Published in J Virol on February 06, 2008
CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses (2010) 0.91
Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations. J Virol (2014) 0.84
Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. J Transl Med (2009) 0.82
Natural anti-CCR5 antibodies in HIV-infection and -exposure. J Transl Med (2011) 0.79
Class B β-arrestin2-dependent CCR5 signalosome retention with natural antibodies to CCR5. Sci Rep (2016) 0.75
The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1. Front Immunol (2017) 0.75
GROMACS: fast, flexible, and free. J Comput Chem (2005) 27.22
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR (1992) 17.71
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Knowledge-based protein secondary structure assignment. Proteins (1995) 14.08
Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature (2007) 14.06
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem (1968) 11.64
The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry (1992) 9.40
Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem Biophys Res Commun (1983) 9.18
Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res (1990) 6.94
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res (1990) 2.98
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med (1999) 2.54
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol (1998) 2.28
Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol (2002) 2.21
Identification of amino acid residues crucial for chemokine receptor dimerization. Nat Immunol (2004) 2.09
Coreceptors: implications for HIV pathogenesis and therapy. Science (1997) 1.81
Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol (2001) 1.80
The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem (1997) 1.62
Main-chain-directed strategy for the assignment of 1H NMR spectra of proteins. Biochemistry (1987) 1.38
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol (2005) 1.25
Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor. J Biol Chem (2001) 1.23
HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A (2000) 1.19
Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol (2005) 1.13
Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J (2002) 1.11
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS (2002) 1.09
Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett (1997) 1.06
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood (2006) 1.03
CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood (2004) 1.02
Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS (2007) 0.94
Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Biochemistry (2004) 0.93
A single-point mutation in the extreme heat- and pressure-resistant sso7d protein from sulfolobus solfataricus leads to a major rearrangement of the hydrophobic core. Biochemistry (1999) 0.88
Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol (2005) 0.87
Exploiting the HIV-chemokine nexus. Science (1997) 0.86
Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? Curr HIV Res (2004) 0.84
Peptide mimotopes selected with HIV-1-blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry. Immunol Cell Biol (2007) 0.79
Recognition of DNA by GAL4 in solution: use of a monomeric protein-DNA complex for study by NMR. Biochemistry (1994) 0.79
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood (2006) 2.88
Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity (2011) 2.82
Molecular architecture of the human sinus node: insights into the function of the cardiac pacemaker. Circulation (2009) 2.58
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS (2009) 2.15
Protection of Sinorhizobium against host cysteine-rich antimicrobial peptides is critical for symbiosis. PLoS Biol (2011) 1.92
Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood (2012) 1.89
Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS (2005) 1.87
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure formation in peptides: a molecular dynamics study. Proc Natl Acad Sci U S A (2002) 1.64
Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A (2012) 1.50
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr (2002) 1.45
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. Chem Biol (2013) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput Biol (2009) 1.43
Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem (2006) 1.39
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis (2007) 1.33
Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res (2005) 1.28
PHOX2B regulates its own expression by a transcriptional auto-regulatory mechanism. J Biol Chem (2005) 1.26
Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem (2002) 1.22
Study of the Villin headpiece folding dynamics by combining coarse-grained Monte Carlo evolution and all-atom molecular dynamics. Proteins (2005) 1.18
Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol (2008) 1.18
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
N-myristoylation determines dual targeting of mammalian NADH-cytochrome b5 reductase to ER and mitochondrial outer membranes by a mechanism of kinetic partitioning. J Cell Biol (2005) 1.14
Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS (2003) 1.13
Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res (2004) 1.12
Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr (2006) 1.09
The role of cytosolic proteins in the insertion of tail-anchored proteins into phospholipid bilayers. J Cell Sci (2009) 1.09
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS (2002) 1.09
Distribution of the pacemaker HCN4 channel mRNA and protein in the rabbit sinoatrial node. J Mol Cell Cardiol (2009) 1.09
Beta-hairpin conformation of fibrillogenic peptides: structure and alpha-beta transition mechanism revealed by molecular dynamics simulations. Proteins (2004) 1.09
The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain (2009) 1.07
Nicotinic acetylcholine receptor subtypes expression during rat retina development and their regulation by visual experience. Mol Pharmacol (2004) 1.07
Molecular simulation of multistate peptide dynamics: a comparison between microsecond timescale sampling and multiple shorter trajectories. J Comput Chem (2008) 1.07
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst (2006) 1.06
Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis (2006) 1.06
Host plant peptides elicit a transcriptional response to control the Sinorhizobium meliloti cell cycle during symbiosis. Proc Natl Acad Sci U S A (2014) 1.06
Abundant and superficial expression of C-type lectin receptors in ectocervix of women at risk of HIV infection. J Acquir Immune Defic Syndr (2009) 1.05
Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses (2010) 1.05
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem (2010) 1.05
Sequence dependence of amyloid fibril formation: insights from molecular dynamics simulations. J Mol Biol (2005) 1.04
Leucine-zipper-mediated homo- and hetero-dimerization of GIT family p95-ARF GTPase-activating protein, PIX-, paxillin-interacting proteins 1 and 2. Biochem J (2003) 1.04
Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin. J Biol Chem (2008) 1.03
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood (2006) 1.03
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood (2004) 1.02
The low-affinity receptor for neurotrophins p75NTR plays a key role for satellite cell function in muscle repair acting via RhoA. Mol Biol Cell (2009) 1.02
Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulations. PLoS Comput Biol (2012) 1.01
Understanding the determinants of stability and folding of small globular proteins from their energetics. Protein Sci (2004) 1.00
Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS One (2009) 1.00
Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis (2007) 0.99
Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology (2007) 0.98
Quantification of Coffea arabica and Coffea canephora var. robusta in roasted and ground coffee blends. Talanta (2012) 0.98
Dynamic diagnosis of familial prion diseases supports the β2-α2 loop as a universal interference target. PLoS One (2011) 0.98
IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J Immunol (2007) 0.98
Effect of hexafluoroisopropanol alcohol on the structure of melittin: a molecular dynamics simulation study. Protein Sci (2005) 0.97
Molecular mechanism of allosteric communication in Hsp70 revealed by molecular dynamics simulations. PLoS Comput Biol (2012) 0.97
Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res (2008) 0.97
Relationship between energy distribution and fold stability: Insights from molecular dynamics simulations of native and mutant proteins. Proteins (2008) 0.96
Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One (2013) 0.96
Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release (2010) 0.96
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget (2010) 0.96
The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci (2010) 0.95
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS (2003) 0.95
Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping. Biophys J (2010) 0.95
Investigating the mechanism of peptide aggregation: insights from mixed monte carlo-molecular dynamics simulations. Biophys J (2008) 0.95
Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS (2007) 0.94
Misfolding of the amyloid beta-protein: a molecular dynamics study. Proteins (2006) 0.94
Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. J Biol Chem (2010) 0.94
Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging (2006) 0.93
Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine (2005) 0.93
Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res (2013) 0.93
Role of cysteine residues and disulfide bonds in the activity of a legume root nodule-specific, cysteine-rich peptide. J Biol Chem (2012) 0.91
Molecular recognition and drug-lead identification: what can molecular simulations tell us? Curr Med Chem (2010) 0.91
MAB21L2, a vertebrate member of the Male-abnormal 21 family, modulates BMP signaling and interacts with SMAD1. BMC Cell Biol (2004) 0.91
CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res (2003) 0.91
Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol (2004) 0.90
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol (2005) 0.90
High sensitivity protein assays on microarray silicon slides. Anal Chem (2009) 0.90
Transcription factor PHOX2A regulates the human alpha3 nicotinic receptor subunit gene promoter. J Biol Chem (2007) 0.90
Kinetics of contact formation and end-to-end distance distributions of swollen disordered peptides. Biophys J (2009) 0.90
Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide. Chemistry (2008) 0.89
A multiscale approach to characterize the early aggregation steps of the amyloid-forming peptide GNNQQNY from the yeast prion sup-35. PLoS Comput Biol (2011) 0.89
Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology (2013) 0.89
CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles. PLoS One (2011) 0.89
Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther (2012) 0.89
Performance Assessment in Fingerprinting and Multi Component Quantitative NMR Analyses. Anal Chem (2015) 0.89
CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J (2008) 0.88
Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. Cancer Res (2008) 0.88